Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagonist Therapeutics

84.61
+1.371.65%
Post-market: 84.60-0.0100-0.01%19:54 EST
Volume:755.42K
Turnover:64.08M
Market Cap:5.29B
PE:117.48
High:85.90
Open:82.18
Low:82.06
Close:83.24
52wk High:93.25
52wk Low:33.31
Shares:62.52M
Float Shares:43.15M
Volume Ratio:0.75
T/O Rate:1.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.7202
EPS(LYR):4.47
ROE:7.80%
ROA:1.82%
PB:8.20
PE(LYR):18.93

Loading ...

H.C. Wainwright Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX)

TIPRANKS
·
5 hours ago

Protagonist Therapeutics Is Maintained at Buy by Citigroup

Dow Jones
·
Nov 11

Stock Track | Protagonist Therapeutics Soars 5.11% Following Analyst Price Target Hikes

Stock Track
·
Nov 11

Stock Track | Protagonist Therapeutics Soars 5.11% Following Analyst Price Target Increases

Stock Track
·
Nov 11

Protagonist Therapeutics price target raised to $65 from $47 at Goldman Sachs

TIPRANKS
·
Nov 10

Protagonist Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
Nov 08

Protagonist Therapeutics Is Maintained at Market Outperform by Citizens

Dow Jones
·
Nov 07

H.C. Wainwright Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

TIPRANKS
·
Nov 07

Protagonist Therapeutics price target raised to $91 from $74 at Clear Street

TIPRANKS
·
Nov 07

Protagonist Therapeutics Advances Pipeline Amid Financial Loss

TIPRANKS
·
Nov 07

The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following Upcoming Rusfertide Phase 3 Data Presentation

Simply Wall St.
·
Nov 07

Protagonist Therapeutics Q3 net loss widens to $39.3 mln

Reuters
·
Nov 07

Protagonist Therapeutics Q3 EPS $(0.62) Beats $(0.63) Estimate, Sales $4.712M Beat $3.636M Estimate

Benzinga
·
Nov 07

Protagonist Therapeutics Q3 EPS USD -0.62

Reuters
·
Nov 07

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Perspective Therapeutics (CATX)

TIPRANKS
·
Nov 04

Protagonist Therapeutics (PTGX): Assessing Valuation After Breakthrough Phase 2b Results and Johnson & Johnson’s Phase 3 Launch

Simply Wall St.
·
Oct 30

Protagonist Therapeutics price target raised to $88 from $76 at Truist

TIPRANKS
·
Oct 28

Truist Raises Price Target on Protagonist Therapeutics to $88 From $76, Keeps Buy Rating

MT Newswires Live
·
Oct 28

Truist Financial Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)

TIPRANKS
·
Oct 28

Protagonist Therapeutics: Promising Prospects and Increased Price Target Amidst Positive Study Data and Strategic Partnerships

TIPRANKS
·
Oct 28